<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Post-translational <z:chebi fb="0" ids="15358">histone</z:chebi> modifications are known to be altered in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> tissues, and differences in the <z:chebi fb="0" ids="15358">histone</z:chebi> modification levels have recently been used to predict the clinical outcome in patients with certain types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we evaluated the immunohistochemical staining patterns of <z:chebi fb="0" ids="15358">histone</z:chebi> H3 dimethylation and acetylation in metachronous <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> of colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> and examined its correlation with patient prognosis </plain></SENT>
<SENT sid="2" pm="."><plain>Double 2Â mm core tissue microarrays were made from 54 paraffin-embedded samples of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> from colorectal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, and were examined by an immunohistochemical analysis of <z:chebi fb="0" ids="15358">histone</z:chebi> H3 lysine 4 (H3K4) dimethylation, <z:chebi fb="0" ids="15358">histone</z:chebi>, H3 lysine 9 (H3K9) dimethylation and <z:chebi fb="0" ids="15358">histone</z:chebi> H3 lysine 9 (H3K9) acetylation </plain></SENT>
<SENT sid="3" pm="."><plain>Positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell staining for each <z:chebi fb="0" ids="15358">histone</z:chebi> modification was used to classify patients into low- and high-staining groups, which were then examined for correlations with the clinicopathological parameters and clinical outcome </plain></SENT>
<SENT sid="4" pm="."><plain>Dimethylation of H3K4 correlated with the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> histological type (P=0.043), and acetylation of H3K9 correlated with the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> histological type (P=0.016) </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, lower levels of H3K4 dimethylation correlated with a poor survival rate (P=0.035) </plain></SENT>
<SENT sid="6" pm="."><plain>The multivariate survival analysis showed that the H3K4 dimethylation status is an independent prognostic factor for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients (P=0.011) </plain></SENT>
<SENT sid="7" pm="."><plain>We suggest that the pattern of <z:chebi fb="0" ids="15358">histone</z:chebi> modification as detected by immunohistochemistry may be an independent prognostic factor for metachronous <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> of colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
</text></document>